The objective of this new cancer treatment technology is to apply ultra-low voltage encoded cellular signals to rapidly injure a tumor’s communication system and trigger the cancer cells’ suicide (apoptosis), while causing no adverse effects to the surrounding healthy tissue.
The technology takes advantage of the fact that malignant cells in a tumor communicate with one-another. This makes it possible for the treatment-codes to be transmitted from cancer cell to cancer cell, wrecking and shutting-down its cellular electrical communication process.
C3 is the exclusive licensee to market and sell the patented technology in the United States and China from Neuro Code Tech Holdings, LLC for the cancer treatment approaches described in the issued patent and three pending patents. The three additional pending U.S. patent applications are as follows:
U.S. Patent Application Serial No. 12/334,212 entitled “Method to Switch-Off Cancer Cell Electrical Communication Codes as Medical Therapy”.
U.S. Patent Application Serial No. 12/936,778 entitled “System and Method to Elicit Apoptosis in Malignant Tumor Cells for Medical Therapy”.
U.S. Patent Application Serial No. 12/812,576 entitled “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy”
This cancer killing technology has the potential to replace current chemotherapy approaches, and represents the dawn of an entirely new treatment approach using tiny encoded signals to destroy cancer, quickly. This new and exciting breakthrough is based on the fact that all cells communicate, including cancer cells. This approach should “signal” the cancer cells to kill themselves.
About Cancer-Code Corporation
C3, located in Albuquerque, NM, is focusing on the development and testing of cancer treatment technology that takes advantage of the fact that all cells have an electrical process and adjacent cells communicate with one another. The approach of C3 is geared toward this cancer cell communication and “wrecking"
Additional information about Cancer-Code Corporation can be found at www.cancercodecorp.com
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, success of demonstration trials, acceptance and demand for new products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
117 Bryn Mawr Dr S.E.
Albuquerque, NM 87106
Tel. (505) 314-1300